Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer

The goal of this clinical trial is to explore the feasibility of a new mode of chemotherapy and bevacizumab induction therapy combined with immunotherapy as first-line treatment for patients with initially unresectable metastatic colorectal cancer (MSS). The main questions it aims to answer are: 1. To explore the efficacy and safety of this treatment mode 2. Try to study treatment benefit the characteristics of the crowd Participants will combined with immunotherapy after chemotherapy and bevacizumab induction therapy.

Trial Details

NCT ID

NCT06176885

Phase

PHASE2

Sponsor

yue junhan

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

• Camrelizumab

Locations (sample)

• Jinhua, Zhejiang, China|29.10678,119.64421

Key Eligibility Criteria

• Patients voluntarily participated in the study signed the informed consent and had good compliance
• Body weight ≥40kg
• Metastatic colorectal cancer confirmed by histology and/or cytology and initially unresectable
• Microsatellite instable (MSS) or proficient Mismatch Repair (pMMR)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →